Abstract: Biguanide compounds and salts thereof are disclosed. Also disclosed are pharmaceutical compositions and therapeutic methods for treating certain diseases including cancer such as breast cancer.

Abstract: Porous networks are described linked by boronates. Also described are processes for producing the porous networks. The porous networks are formed by reacting a polyboronic acid with itself or with a polydiol, a polydiamine, or a polyamino alcohol. The resulting boronate linkage is covalently bonded. The characteristics and properties of the resulting porous material can be varied and altered by changing the reactants and by incorporating functional groups into the reactants. Of particular advantage, the porous materials can be formed at or near atmospheric pressure and at low temperature in the presence of one or more solvents.

Abstract: The present invention provides a new method for detecting or monitoring a liver disease in a subject that has no indication of any liver pathologies, by measuring the amount of concentration of albumin mRNA in an acellular blood sample from the subject, and then comparing the amount or concentration of albumin mRNA with a standard control.

Abstract: A driving support device includes a cross direction control device and a cross direction alarm device which are a first support unit that performs drive support of steering of a vehicle, a traveling direction control device and a traveling direction alarm device which are a second support unit that performs drive support of deceleration of the vehicle, and a running support processing device that controls the first support unit and the second support unit. The running support processing device detects looking-aside of a driver, detects a non-drive manual operation of the driver, and sets a level of an effect of detection of the non-drive manual operation to an effect of detection of the looking-aside in the first support unit to be greater than a level of an effect of detection of the non-drive manual operation to an effect of detection of the looking-aside in the second support unit.

Abstract: Disclosed are methods for preparing and screening for an inhibitor of the activity of a biological molecule having a catalytic or non-catalytic cysteine residue. The methods including preparing a library of candidate inhibitor molecules by conjugating an electrophile to a plurality of drug molecules where the library of candidate inhibitor molecules thus formed react with cysteine residues. The library of candidate inhibitor molecules then may be reacted with the biological molecule to identify those inhibitor molecule that react with the catalytic or non-catalytic cysteine residue of the biological molecule in order to identify an inhibitor of the biological molecule.

Abstract: The present invention provides for a genetically modified host cell capable of producing isopentenol and/or 3-methyl-3-butenol, comprising (a) an increased expression of phosphomevalonate decarboxylase (PMD) (b) an increased expression of a phosphatase capable of converting isopentenol into 3-methyl-3-butenol, (c) optionally the genetically modified host cell does not express, or has a decreased expression of one or more of NudB, phosphomevalonate kinase (PMK), and/or PMD, and (d) optionally one or more further enzymes capable of converting isopentenol and/or 3-methyl-3-butenol into a third compound, such as isoprene.

Abstract: The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula (I) have the structure: wherein A, B, W, Y, Z, R2, R4, R5, R6, Rq and q are as defined herein. The compounds can be used as inhibitors of Bcl-3 and can be used for the treatment of cancer, particularly metastatic cancer.

Abstract: A radio-frequency (RF) body-coupled communications (BCC) transceiver is disclosed according to one embodiment of the present disclosure. The RF BCC transceiver includes an RF BCC transmitter and an RF BCC receiver, such that the RF BCC transmitter transmits an RF signal to the RF BCC receiver via a body area network (BAN) of a human body.

Abstract: Object and shape detection in digital images utilizing edge detection is described. In a first edge detection approach, phase transformation is utilized in the frequency domain, such as in response to Fourier transform, followed by use of a frequency-domain phase kernel and inverse-Fourier transform. Edge detection is also provided using a phase transform in the spatial domain utilizing a convolution approach. In a second edge detection approach, phase stretching is utilized, such as in combination with phase histogramming along with thresholding and morphological operations. Numerous example images are provided illustrating benefits of the disclosed technology with different applications and under different conditions.

Abstract: A node in a wireless network includes a memory, transceiver, and processor operatively coupled to one another. The memory stores a signature of the node. The transceiver is configured to transmit, during an initial frame, the signature to one or more neighboring nodes, and receive, during the initial frame, a first signal that includes one or more signatures of the one or more neighboring nodes. The transceiver is also configured to transmit, during a repetition frame, a scrambled waveform of the first signal received during the initial frame, and receive, during the repetition frame, a second signal that includes a retransmission of signals received by the one or more neighboring nodes during the initial frame. The processor is configured to determine a distance from the node to each of the one or more neighboring nodes based at least in part on the first signal and the second signal.

Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

Abstract: The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.

Abstract: A Fe(II)- and Ca+2-chelated alginate/gelatin conjugate.

Abstract: The instant invention relates to a method for noise reduction from a magnetic resonance sounding (MRS) oscillating signal, and more particularly, to a data processing method for reducing random noise contained in MRS oscillating signal based on joint algorithm principles of EMD and TFPF. A MRS oscillating signal is decomposed into different eigen-mode components by using decomposition characteristic of EMD algorithm; then a signal-dominated eigen-mode component is encoded as an instantaneous frequency of an analytical signal of unit amplitude using TFPF algorithm; and random noise is suppressed with the characteristics that the time-frequency distribution of the analytical signal is concentrated along with the instantaneous frequency. The method requires fewer filtering constraints and is simple to operate without need of designing a filtering interval in the time-frequency domain, and has good adaptability to the MRS oscillating signal with a low signal-noise-ratio.

Abstract: An amorphous thin film stack can include a first layer including a combination metals or metalloids including: 5 at % to in 90 at % of a metalloid; 5 at % to 90 at % of a first metal and a second metal independently selected from titanium, vanadium, chromium, iron, cobalt, nickel, niobium, molybdenum, ruthenium, rhodium, palladium, tantalum, tungsten, osmium, iridium, or platinum. The three elements may account for at least 70 at % of the amorphous thin film stack. The stack can further include a second layer formed on a surface of the first layer. The second layer can be an oxide layer, a nitride layer, or a combination thereof. The second layer can have an average thickness of 10 angstroms to 200 microns and a thickness variance no greater than 15% of the average thickness of the second layer.

Abstract: Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.

Abstract: A system and method for controlling metabolic enzymes or pathways in cells to produce a chemical above the levels of a wild-type strain is disclosed. The system utilizes cells, including yeasts, bacteria, and molds, having at least two genes capable of being controlled bi-directionally with light, where one gene is turned from off to on when exposed to light and another gene is turned from on to off when exposed to light, the two genes reversing when the light is turned off. Cells may utilize any number of sequences that benefit chemical production, including sequences that: encode for constitutive transcription of light-activated transcription factor fusions; encode for a metabolic enzyme; encode for a repressor; induce expression of metabolic enzymes; and an endogenous or exogenous activator expressed by a constitutive promoter, inducible promoter, or gene circuit.

Abstract: CAR cells targeting and antibodies human HLA-G are described as a new method of cancer treatment. It is proposed that HLA-G CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-G.

Abstract: Polycaprolactone (PCL) scaffolds having macropores interconnected with micorpores are provided. Tissue grafts that include the PCL scaffold having therapeutic cells encapsulated within the macropores are also provided. Also provided are methods of making the PCL scaffold and the tissue graft, and methods of transplanting cells into an individual using the tissue graft.

Abstract: The present invention relates to a method for inhibiting activity of a protein selected from the group consisting of KDM4A, KDM4B, and KDM4C, comprising the step of exposing the protein to an effective inhibiting amount of a compound having the formula wherein R1 is H or C7O5H8; R2 is H, OH, or OCH3; and R3 is H or OH. The present invention also relates to a method for treating or lessening the severity of a disease, condition, or disorder in which modulation of KDM4A, KDM4B, or KDM4C is beneficial, which method comprises administering to a subject suffering from said disease, condition, or disorder a therapeutically-effective amount of: a) a compound having the formula wherein R1 is H or C7O5H8; R2 is H, OH, or OCH3; and R3 is H or OH; or b) a composition comprising the compound and a pharmaceutically acceptable adjuvant, vehicle, or carrier.